Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Targovax ASA: Interim Report second quarter and first half year 2016 | ||
By: Nasdaq / GlobeNewswire - 25 Aug 2016 | Back to overview list |
|
Oslo, Norway, 25 August 2016 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, announces its second quarter and first half year 2016 results. A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET and a conference call will take place at 14.00 CET (details below). Highlights:
In July 2016, Targovax raised NOK 110 million in new equity. The transaction closed on 7 July 2016 and Targovax listed the next day on Oslo Axess under the ticker TRVX. "Targovax develops according to plan. I am especially pleased that we recruited our first patient in our mesothelioma trial and that we could present positive data for our peptide immune therapy. The recent IPO means that we have funding to start and get data from six new trials", says CEO Gunnar Gårdemyr. ###
Presentation
Hotel Continental
The presentation will also be webcast live and can be accessed through www.targovax.com.
Conference call
Call-in numbers:
Access code: 72735642# Please make sure to dial in at least 5-10 minutes ahead to complete your registration.
See attached list for more dial-in numbers.
Reporting material
For further information, please contact
Gunnar Gårdemyr, CEO
Øystein Soug, CFO
Arming the patient's immune system to fight cancer
ONCOS-102 is a product candidate derived from a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment is designed to reactivate the immune system's capacity to recognize and attack cancer cells. The product candidates TG01 and TG02 constitute a peptide-based immunotherapy platform targeting the difficult to treat RAS mutations found in more than 85% of pancreatic cancers, 50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards demonstrating that TG vaccines will prolong time to cancer progression and increase survival. These product candidates will be developed in combination with multiple treatments, including checkpoint inhibitors in several cancer indications. Targovax also has a number of other cancer immune therapy candidates in the early stages of development. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Targovax_Second quarter and first half 2016 report
Targovax_Second quarter and first half 2016 presentation
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Targovax ASA via GlobeNewswire
HUG#2037133
|
||
|
||
Copyright 2016 Nasdaq / GlobeNewswire | Back to overview list |